Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
出版年份 2022 全文链接
标题
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-02-17
DOI
10.1016/j.annonc.2022.02.004
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- (2021) P. Schmid et al. ANNALS OF ONCOLOGY
- Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Top 10 Challenges in Cancer Immunotherapy
- (2020) Priti S. Hegde et al. IMMUNITY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
- (2020) G. Bianchini et al. ANNALS OF ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
- (2018) D A Yardley et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
- (2015) M. Callari et al. CLINICAL CANCER RESEARCH
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- (2014) R. M. Connolly et al. JOURNAL OF NUCLEAR MEDICINE
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
- (2010) Takayuki Iwamoto et al. JNCI-Journal of the National Cancer Institute
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search